Acorda Therapeutics (FRA:CDG) Total Stockholders Equity : €-170.9 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Total Stockholders Equity?

Acorda Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €-170.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Acorda Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €-137.60. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Acorda Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was -1.05.

Acorda Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Acorda Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Total Stockholders Equity Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

279.74

195.60

133.76

88.38

-144.85

Acorda Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															71.88	62.64	55.24	-144.85	-170.91

Acorda Therapeutics (FRA:CDG) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Acorda Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-170.909	-	0)	/	1.2421
	=	-137.60

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Acorda Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(177.627	+	2.619)	/	-170.909
	=	-1.05

Acorda Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (FRA:CDG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ACOR:USA

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines